NCT05148884 - Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 9, 2021

Primary Completion Date

January 18, 2023

Study Completion Date

January 18, 2023

Conditions

Medication-Induced Dyskinesia

Interventions

DRUG

NLX-112

NLX-112 will be supplied as tablets containing 0.25 mg NLX-112. NLX-112 is a structurally novel centrally acting, high-efficacy selective 5-HT1A receptor agonist with nanomolar affinity for 5-HT1A receptors. Proposed as a treatment for L-DOPA-induced-dyskinesia in Parkinson's disease.

DRUG

Placebo

Placebo will be matching tablets (identical weight, shape and color) without NLX-112.

Trial Locations (5)

413 45

Sahlgrenska Hospital, Gothenburg

221 85

Skåne University Hospital, Lund

113 65

ASC Torsplan, Stockholm

171 76

Karolinska University Hospital, Solna, Stockholm

752 37

CTC Clinical Trial Consultants AB (CTC), Uppsala